These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 30864675)

  • 1. Targeting excessive MYCN expression using MLN8237 and JQ1 impairs the growth of hepatoblastoma cells.
    Eberherr C; Beck A; Vokuhl C; Becker K; Häberle B; Von Schweinitz D; Kappler R
    Int J Oncol; 2019 May; 54(5):1853-1863. PubMed ID: 30864675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Killing of Human Neuroblastoma Cells by the Small Molecule JQ1 Occurs in a p53-Dependent Manner.
    Mazar J; Gordon C; Naga V; Westmoreland TJ
    Anticancer Agents Med Chem; 2020; 20(13):1613-1625. PubMed ID: 32329693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MYCNOS functions as an antisense RNA regulating MYCN.
    Vadie N; Saayman S; Lenox A; Ackley A; Clemson M; Burdach J; Hart J; Vogt PK; Morris KV
    RNA Biol; 2015; 12(8):893-9. PubMed ID: 26156430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The long non-coding RNA MYCNOS-01 regulates MYCN protein levels and affects growth of MYCN-amplified rhabdomyosarcoma and neuroblastoma cells.
    O'Brien EM; Selfe JL; Martins AS; Walters ZS; Shipley JM
    BMC Cancer; 2018 Feb; 18(1):217. PubMed ID: 29466962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of
    Beck A; Trippel F; Wagner A; Joppien S; Felle M; Vokuhl C; Schwarzmayr T; Strom TM; von Schweinitz D; Längst G; Kappler R
    Clin Epigenetics; 2018; 10():27. PubMed ID: 29507645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MYCN contributes to the malignant characteristics of erythroleukemia through EZH2-mediated epigenetic repression of p21.
    Liu L; Xu F; Chang CK; He Q; Wu LY; Zhang Z; Li X
    Cell Death Dis; 2017 Oct; 8(10):e3126. PubMed ID: 29022893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CTCF cooperates with noncoding RNA MYCNOS to promote neuroblastoma progression through facilitating MYCN expression.
    Zhao X; Li D; Pu J; Mei H; Yang D; Xiang X; Qu H; Huang K; Zheng L; Tong Q
    Oncogene; 2016 Jul; 35(27):3565-76. PubMed ID: 26549029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects.
    Shahbazi J; Liu PY; Atmadibrata B; Bradner JE; Marshall GM; Lock RB; Liu T
    Clin Cancer Res; 2016 May; 22(10):2534-44. PubMed ID: 26733615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Novel MYCN-Specific Antigene Oligonucleotide Deregulates Mitochondria and Inhibits Tumor Growth in MYCN-Amplified Neuroblastoma.
    Montemurro L; Raieli S; Angelucci S; Bartolucci D; Amadesi C; Lampis S; Scardovi AL; Venturelli L; Nieddu G; Cerisoli L; Fischer M; Teti G; Falconi M; Pession A; Hrelia P; Tonelli R
    Cancer Res; 2019 Dec; 79(24):6166-6177. PubMed ID: 31615807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1 Is a Therapeutic Target of the Bromodomain Inhibitor JQ1 and, Combined with HLA Class I, a Promising Prognostic Biomarker in Neuroblastoma.
    Melaiu O; Mina M; Chierici M; Boldrini R; Jurman G; Romania P; D'Alicandro V; Benedetti MC; Castellano A; Liu T; Furlanello C; Locatelli F; Fruci D
    Clin Cancer Res; 2017 Aug; 23(15):4462-4472. PubMed ID: 28270499
    [No Abstract]   [Full Text] [Related]  

  • 11. Hepatoblastomas exhibit marked
    Rivas MP; Aguiar TFM; Maschietto M; Lemes RB; Caires-Júnior LC; Goulart E; Telles-Silva KA; Novak E; Cristofani LM; Odone V; Cypriano M; de Toledo SRC; Carraro DM; Escobar MQ; Lee H; Johnston M; da Costa CML; da Cunha IW; Tasic L; Pearson PL; Rosenberg C; Timchenko N; Krepischi ACV
    Tumour Biol; 2020 Dec; 42(12):1010428320977124. PubMed ID: 33256542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1.
    Jacques C; Lamoureux F; Baud'huin M; Rodriguez Calleja L; Quillard T; Amiaud J; Tirode F; Rédini F; Bradner JE; Heymann D; Ory B
    Oncotarget; 2016 Apr; 7(17):24125-40. PubMed ID: 27006472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and experimental validation of druggable epigenetic targets in hepatoblastoma.
    Clavería-Cabello A; Herranz JM; Latasa MU; Arechederra M; Uriarte I; Pineda-Lucena A; Prosper F; Berraondo P; Alonso C; Sangro B; García Marin JJ; Martinez-Chantar ML; Ciordia S; Corrales FJ; Francalanci P; Alaggio R; Zucman-Rossi J; Indersie E; Cairo S; Domingo-Sàbat M; Zanatto L; Sancho-Bru P; Armengol C; Berasain C; Fernandez-Barrena MG; Avila MA
    J Hepatol; 2023 Oct; 79(4):989-1005. PubMed ID: 37302584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BET and Aurora Kinase A inhibitors synergize against MYCN-positive human glioblastoma cells.
    Čančer M; Drews LF; Bengtsson J; Bolin S; Rosén G; Westermark B; Nelander S; Forsberg-Nilsson K; Uhrbom L; Weishaupt H; Swartling FJ
    Cell Death Dis; 2019 Nov; 10(12):881. PubMed ID: 31754113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IMPDH2 suppression impedes cell proliferation by instigating cell cycle arrest and stimulates apoptosis in pediatric hepatoblastoma.
    Li L; Wu Y; Huang HT; Yong JK; Lv Z; Zhou Y; Xiang X; Zhao J; Xi Z; Feng H; Xia Q
    J Cancer Res Clin Oncol; 2024 Aug; 150(8):377. PubMed ID: 39085725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GREB1 induced by Wnt signaling promotes development of hepatoblastoma by suppressing TGFβ signaling.
    Matsumoto S; Yamamichi T; Shinzawa K; Kasahara Y; Nojima S; Kodama T; Obika S; Takehara T; Morii E; Okuyama H; Kikuchi A
    Nat Commun; 2019 Aug; 10(1):3882. PubMed ID: 31462641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Silencing of the Long Noncoding RNA MYCNOS1 Suppresses Activity of MYCN-Amplified Retinoblastoma Without RB1 Mutation.
    Saengwimol D; Chittavanich P; Laosillapacharoen N; Srimongkol A; Chaitankar V; Rojanaporn D; Aroonroch R; Suktitipat B; Saisawang C; Svasti S; Hongeng S; Kaewkhaw R
    Invest Ophthalmol Vis Sci; 2020 Dec; 61(14):8. PubMed ID: 33270844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications.
    Carrillo-Reixach J; Torrens L; Simon-Coma M; Royo L; Domingo-Sàbat M; Abril-Fornaguera J; Akers N; Sala M; Ragull S; Arnal M; Villalmanzo N; Cairo S; Villanueva A; Kappler R; Garrido M; Guerra L; Sábado C; Guillén G; Mallo M; Piñeyro D; Vázquez-Vitali M; Kuchuk O; Mateos ME; Ramírez G; Santamaría ML; Mozo Y; Soriano A; Grotzer M; Branchereau S; de Andoin NG; López-Ibor B; López-Almaraz R; Salinas JA; Torres B; Hernández F; Uriz JJ; Fabre M; Blanco J; Paris C; Bajčiová V; Laureys G; Masnou H; Clos A; Belendez C; Guettier C; Sumoy L; Planas R; Jordà M; Nonell L; Czauderna P; Morland B; Sia D; Losic B; Buendia MA; Sarrias MR; Llovet JM; Armengol C
    J Hepatol; 2020 Aug; 73(2):328-341. PubMed ID: 32240714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JQ1 suppresses tumor growth via PTEN/PI3K/AKT pathway in endometrial cancer.
    Qiu H; Li J; Clark LH; Jackson AL; Zhang L; Guo H; Kilgore JE; Gehrig PA; Zhou C; Bae-Jump VL
    Oncotarget; 2016 Oct; 7(41):66809-66821. PubMed ID: 27572308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Knockdown of
    Liu L; Cui Z; Zhang J; Wang J; Gu S; Ma J; Chen H; Hang L; Yang J; Shi Y
    Cancer Biother Radiopharm; 2020 Feb; 35(1):41-49. PubMed ID: 31916845
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.